{"id":"W3191554850","doi":"10.1177/17588359211036544","title":"IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Bevacizumab; Gemcitabine; Clinical endpoint; Oncology; Chemotherapy; Internal medicine; Tumor microenvironment; Cancer; Immunotherapy; Clinical trial; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004584745,0.0002964978,0.001912336,0.0001512483,0.00004996193,0.000003599078,0.0001128213,0.000191945,0.0002515432],"category_scores_gemma":[0.0001659335,0.0001882134,0.00009110259,0.0004433282,0.0008898517,0.0001255838,0.00005278041,0.0004759378,3.529044e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002235932,"about_ca_system_score_gemma":0.0009157901,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004594435,"about_ca_topic_score_gemma":0.000592226,"domain_scores_codex":[0.9974998,0.0003133359,0.0007090353,0.0004831827,0.0006003777,0.0003943205],"domain_scores_gemma":[0.9984328,0.0007097904,0.000264764,0.0002629648,0.0001659496,0.0001637324],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6220774,0.004059997,0.01193066,0.00009138121,0.0002247648,0.0001917111,0.001377425,0.000004339158,0.00002238007,0.0000760559,0.000004081866,0.3599398],"study_design_scores_gemma":[0.9512857,0.02172803,0.02162162,0.0004664159,0.0002364826,0.0000373351,0.0004484524,0.0001154456,0.0002218401,0.0003554779,0.003258452,0.0002247131],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9763733,0.01626422,0.0001121526,0.004477582,0.0002160126,0.001761143,0.000009855665,0.00002179536,0.000764006],"genre_scores_gemma":[0.9836195,0.01343597,0.0005465235,0.001839345,0.00007617744,0.0003782299,0.00002725543,0.00003223626,0.00004475678],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3597151,"threshold_uncertainty_score":0.767512,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01165188480779092,"score_gpt":0.3378004446659155,"score_spread":0.3261485598581245,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}